Amgen CEO says weight loss drug can address 'patient persistence issue'

Monday - Friday, 6:00 - 7:00 PM ET

Amgen

CEO Bob Bradway told CNBC’s Jim Cramer he thinks his company’s obesity drug can help patients manage weight loss long term, which he indicated is a challenge.

“We think we can address one of the reasons that the field is struggling a little bit, which is the patient persistence issue,” Bradway said.

Amgen revealed Monday that a trial of its experimental GLP-1 drug, MariTide, showed that patients were able to maintain weight loss for two years when given a monthly injection. Right now, most widely-used weight loss injections are taken weekly.